Watching a small-cap company come into its own is like watching a plant grow. As investors, we provide the nutrients to help it grow, hoping that the seed of an idea takes root. If we're lucky, that company will grow and will start to bear fruit in the form of shareholder value. Obviously, not all of these companies will take root, but even the ones that do take time to go from seedling to harvest. This is where many investors in Solazyme (NASDAQ:TVIA) are right now, waiting for a seedling to bear fruit.
Let's take a quick look at what's going on at Solazyme and when we can expect this company to start bearing shareholder value.
The wait is the hardest part
Solazyme's projects are a botanist's dream. This is a company that uses algae to produce a wide variety of products ranging from engine lubricants to jet fuel and skin products. Its efforts have garnered lots of attention from a wide array of potential partners. While there are several consumer-related ideas the company is pursuing, some of its more interesting projects involve working with the U.S. government, as the departments of Defense and Energy have both participated in research projects involving the production and use of biodiesel created from algal oils. The DOD hopes that these oils could be used as a replacement fuel for its diesel-powered naval vessels.
With this wide range of products, there is a lot of potential. Based on the current products Solazyme is working on, the company estimates a possible market in the range of $10.4 billion to $14.5 billion. One of its first products that has made it to market is the skin-care product Algenist. Product revenue for the anti-aging skin products has nearly tripled year over year, and it generated more than $16 million for the company throughout 2012.
Before we get ahead of ourselves, though, let's keep the company's progress in perspective. Three of its joint venture projects are still in the development phase and won't generate any revenue until the beginning of 2014. One of the major projects to ramp up at that time is the renewable-fuels joint venture with Bunge Limited (NYSE:BG). Their new facility will produce up to 300,000 metric tons of renewable fuel.
On the other hand, there are some very strong indicators for this company. Not only has it secured enough financing through 2014, but it also has backing from major companies through those joint ventures. Along with Bunge, Solazyme has also entered into partnerships with Chevron (NYSE:CVX), Dow Chemical (NYSE:DOW), and Unilever to develop renewable products from algal oils. If these large companies all have a stake in Solazyme's success, then surely there's potential in the company's ideas.
The company's two largest threats are its competitors, and low energy prices. Amyris (NASDAQ:AMRS) is its most direct competitor that also offers a wide range of offerings and products from natural byrpduct oils. The company has developed a method that uses microbes such as yeast instead of algae to synthesize oils. Some may also consider Rentech (NASDAQ:RTK) a direct competitor, but its finished products are more fuel related and less diverse than Solazyme's.
A much greater threat to Solazyme in the near term is energy prices. The low cost of both natural gas and oil will make it difficult for the company to sell into the alternative-fuels markets if traditional fuel prices make the switching costs not commercially viable.
What a Fool believes
Solazyme investors need patience. It's best to look at the Algenist products as the first bud on a young plant. They're a foreshadowing of things to come, and they'll help slow the cash burn, but they're still not a significant contribution.
Early 2014 will be a strong indicator of the company's success. Once customers get to see the types of offerings available, we'll have a clearer picture of the market demand the company can expect. Even if these products do look promising to consumers, though, it will probably still be a long time until the company can realize a significant fraction of that potential market.
If you don't want to wait until 2014 for an investment to start to pay off, check out The Motley Fool's chief investment officer's No. 1 stock for year. Find out which stock it is in the brand-new free report: "The Motley Fool's Top Stock for 2013." Just click here to access the report and find out the name of this under-the-radar company.
Fool contributor Tyler Crowe has no position in any stocks mentioned. You can follow him on Fool.com under TMFDirtyBird, Google +, or Twitter: @TylerCroweFool.
The Motley Fool recommends Chevron and owns shares of Solazyme. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.